Stay updated on BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.

Latest updates to the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page
- ChecktodayChange DetectedThe site’s displayed revision identifier changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check7 days agoChange DetectedThe study record for the completed Phase 2 BTX 1204 atopic dermatitis trial is displayed, including its design, eligibility criteria, locations, and outcome measures.SummaryDifference60%

- Check14 days agoChange DetectedThe footer’s revision identifier changes from v3.7.2 to v3.8.0, while the page remains a 403 Forbidden error screen.SummaryDifference0.2%

- Check28 days agoChange DetectedAn NIH-wide banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence,” and the site revision advances from v3.7.1 to v3.7.2. The study page itself continues to show a 403 error.SummaryDifference1%

- Check42 days agoChange DetectedThe site revision displayed on the 403 Forbidden error page changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, blocking access to the study record; the usual study content and navigation are replaced by an access-denied message.SummaryDifference18%

Stay in the know with updates to BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.